Comparing Epirus Biopharmaceuticals (EPRS) & The Competition
Epirus Biopharmaceuticals (NASDAQ: EPRS) is one of 95 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Epirus Biopharmaceuticals to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, institutional ownership and valuation.
Valuation & Earnings
This table compares Epirus Biopharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Epirus Biopharmaceuticals Competitors||$224.58 million||$57.96 million||-1.20|
Epirus Biopharmaceuticals’ competitors have higher revenue and earnings than Epirus Biopharmaceuticals. Epirus Biopharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent ratings and price targets for Epirus Biopharmaceuticals and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Epirus Biopharmaceuticals Competitors||123||465||1163||11||2.60|
As a group, “Biotechnology” companies have a potential upside of 58.89%. Given Epirus Biopharmaceuticals’ competitors higher possible upside, analysts plainly believe Epirus Biopharmaceuticals has less favorable growth aspects than its competitors.
Volatility and Risk
Epirus Biopharmaceuticals has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500. Comparatively, Epirus Biopharmaceuticals’ competitors have a beta of 1.13, suggesting that their average share price is 13% more volatile than the S&P 500.
This table compares Epirus Biopharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Epirus Biopharmaceuticals Competitors||-910.58%||-183.99%||-27.07%|
Institutional & Insider Ownership
20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 19.6% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Epirus Biopharmaceuticals competitors beat Epirus Biopharmaceuticals on 7 of the 8 factors compared.
Epirus Biopharmaceuticals Company Profile
EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company’s products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.
Receive News & Ratings for Epirus Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epirus Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.